Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin
about
Human IgG4: a structural perspectiveStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsThe clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaAntibody-drug conjugates as novel anti-cancer chemotherapeuticsThe development of immunoconjugates for targeted cancer therapyStructure-Guided Functional Characterization of Enediyne Self-Sacrifice Resistance Proteins, CalU16 and CalU19Current Status: Site-Specific Antibody Drug ConjugatesSpontaneous Isopeptide Bond Formation as a Powerful Tool for Engineering Site-Specific Antibody-Drug Conjugates.Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.Neoglycosylation and neoglycorandomization: Enabling tools for the discovery of novel glycosylated bioactive probes and early stage leads.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromesSiglec-mediated regulation of immune cell function in disease.Antibody therapeutics in cancer.On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxTherapeutic antibodies against cancer.Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studiesMonoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaStructural dynamics of a methionine γ-lyase for calicheamicin biosynthesis: Rotation of the conserved tyrosine stacking with pyridoxal phosphate.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinTarget Therapy in Hematological Malignances: New Monoclonal Antibodies.Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.Antibody therapy for pediatric leukemia.Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.Antibody-drug conjugates - a perfect synergy.Designing immunoconjugates for cancer therapy.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsDrug-conjugated antibodies for the treatment of cancer.Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Targeting CD22 in B-cell malignancies: current status and clinical outlook.CD33 in Alzheimer's disease.Microbial natural products: molecular blueprints for antitumor drugs.Novel drugs for older patients with acute myeloid leukemia.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug ConjugatesBeyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.
P2860
Q26779758-FA718EF5-D2F4-4E26-8EC4-0B656C242A75Q26780335-A9F1C4F8-D530-4B4D-ABC2-B7812CE9379DQ26783425-ED63C7AB-3F52-490C-90EE-F178349B097EQ26800175-CD3EFBBA-4CD3-424E-B852-6EB79122A3C0Q27021990-86685738-B4C0-4CF3-8F8B-9EF4243C0043Q27684894-BD31B890-9535-4E05-BC28-A80C2483A5F2Q28829290-2B5BF31D-B1B0-412F-9EA0-CACDDD0AAD6BQ30396530-532D67C0-C55F-4A5F-BBF3-724369D07A68Q31149399-A9798116-078B-4343-8DCF-C97C67679D7AQ33951389-A3C04E7D-60A9-4F97-984D-17C32A1B85CCQ34172042-866FECFF-5EFB-4439-BB84-B7A9D69C3C38Q34300698-CFE3FF8F-03DF-403D-9DE1-D581B40EEDCEQ34314957-9D5537F4-A383-48F0-89EA-0B56BD3CBF96Q34370627-1CA51148-B8E4-4C25-80F3-5792AF9402F2Q34677175-19F77B59-0A40-488C-9007-068ABCD2E580Q35446035-38069C80-D844-491D-B1EB-423319C4976EQ35908498-E4B539C1-C4B7-4C94-AFFB-59F5907D9862Q35992503-0061866B-4777-444A-BA29-FCE5FDFBBA61Q36180078-154E1EF5-7942-441C-8ED2-239D572EDB09Q36339717-30DA1FF3-E93F-4591-BB1C-BADE707B5C70Q36853353-7EA63753-10B7-46BD-BC4C-C479EA2DF1C9Q36932014-760CD646-5529-4AE9-8032-7E330745E0CAQ36979140-449F15FE-5915-4A4E-AC8E-EF5914B52091Q36996975-6880EFF5-3B21-4EDF-A047-8401FC6DCD7AQ37296134-E99056BD-FCE3-4237-AE07-6C5C08986C44Q37725578-B97F5A77-7C4D-43AE-8DFF-A3C036C4B9A2Q38002447-10A0B725-2CDA-468C-899F-912363142870Q38014923-FBC37D28-1AA1-4C90-8565-7118FCF0C64CQ38017203-EA8BCE1E-0CC7-4B86-AE36-9D1D31BE335FQ38042256-1BA42CDE-D198-4C2E-93D7-E5183B3761C4Q38061647-6EE4E85A-95A2-4236-A291-AD2AF71210ABQ38084826-B4A98704-5012-4F57-B644-5EA50594B100Q38087390-BC46805B-6901-4D8B-9617-3B88764B7EFEQ38094099-5750C340-F5D9-43C3-A0EE-FD1B26E1D5B7Q38108568-7ADFE819-EB40-472A-BBDA-5B273D61DC3BQ38132067-20FE38A4-097E-4B48-8B8F-464B276F8C24Q38133765-C26AF553-A782-4EBC-B1E7-C18D4F7F09ECQ38241761-C9DDC6D4-DB5E-42F6-A3C1-84CE906FA659Q38262066-37AF41BB-DC06-4486-AE33-5C33E4D0B981Q38364462-AA14923D-C837-4721-865B-F0B42AE94143
P2860
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@ast
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@en
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@nl
type
label
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@ast
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@en
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@nl
prefLabel
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@ast
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@en
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@nl
P3181
P1476
Antibody-drug conjugates of ca ...... icin and inotuzumab ozogamicin
@en
P2093
A. D. Ricart
P304
P3181
P356
10.1158/1078-0432.CCR-11-0486
P407
P577
2011-10-15T00:00:00Z